Boston Scientific Corporation Common Stock (NYSE: BSX)
20 Days left to seek lead plaintiff status.
The complaint alleges defendants provided investors with material information concerning Boston Scientific’s expected growth rate for fiscal 2025. Defendants’ statements included, among other things, confidence in the Company’s U.S. EP division’s growth trajectory, strength against competition, and overall contribution to the Company’s net income projections. Defendants repeatedly issued positive statements concerning the sustainability of growth in key product segments and repeatedly elevated full-year guidance metrics while failing to disclose material adverse trends affecting procedure volumes, competitive pressures, as well as regulatory and reimbursement headwinds that ultimately necessitated lowered expectations.